AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03341845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: axitinib in combination with avelumab
Study NCT03341845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: axitinib in combination with avelumab
Study NCT04165356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mouth-rinse with 0.12% clorhexidine
Description: mouthwash with 0.12% chlorhexidine twice daily compared to isotonic bicarbonated solution twice daily for the prevention of any infection associated with mechanical ventilation in patients requiring endotracheal intubation in the intensive care unit of a third level hospital.
Study NCT04165356 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate
Description: mouthwash with sotonic solution with 1.5% sodium bicarbonate twice daily for the prevention of any intection associated with mechanical ventilation
Study NCT04644120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-47D11
Description: Intravenous (IV) infusion.
Study NCT04644120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-47D11
Description: Intravenous (IV) infusion.
Study NCT04644120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-2B04
Description: Intervenous (IV) Infusion
Study NCT04644120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABBV-2B04
Description: Intervenous (IV) Infusion
Study NCT04591756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Qualitative Fit Testing
Description: Qualitative fit testing with denatonium benzoate
Study NCT06392152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Focal Mass Drug Administration with Primaquine
Description: A population census was conducted in each village in August 2019 to record the demographic information and malaria histories of the villagers. Vulnerable groups such as pregnant women, breastfeeding mothers, and children under 7 years were excluded from PQ administration.~Both Group 1 \&2 underwent a preliminary clinical assessment to exclude individuals with G6PD deficiency and low hemoglobin levels.~Based on the WHO malaria treatment guidelines, a standard PQ regimen of 0.25 mg PQ base/kg body weight daily for 14 days was administered through directly observed treatment (DOT) to ensure drug intake and monitor potential adverse effects. The safety of each participant was monitored by follow-up blood testing using Hemocue's hemoglobin photometers to track changes in hemoglobin levels.~As per cross-over design, eligible individulas from Group-1 received PQ-MDA in year 1 and Group-2 received PR-MDA in the following year.
Study NCT01146535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Description: 150 IU lozenges bid for 5 days
Study NCT01146535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 75 mg capsules bid for 5 days
Study NCT01146535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: 75 mg capsules bid for 5 days
Study NCT01146535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maltose
Description: 200 mg maltose lozenges bid for 5 days
Study NCT01992250 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Visica 2 Treatment System
Description: Cryoablation
Study NCT01673984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decapeptyl® SR 22.5mg
Description: 22.5mg, intramuscular injection, given on day 1 / month 0 \& month 6 (+/- 7 days).
Study NCT01673984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg
Description: For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
Study NCT06024811 — intervention group
Intervention type: BEHAVIORAL
Intervention: supporting nursing care
Description: Supportive nursing care was applied during the intrapartum period. Latent Active Transition phase,birt, postpartum period
Study NCT00943592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
Study NCT00943592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Doses ranging from 100 to 140 mg/m2
Study NCT00943592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: 20mg/d x5
Study NCT00943592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Infusion of donor, bone marrow and auto.
Study NCT00878800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXD101
Description: Administered in combination with doxorubicin (BelDox)
Study NCT00878800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered in combination with PXD101 (BelDox)
Study NCT03564769 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Arm
Description: Individuals randomized to the intervention group will receive skin cancer screening educational materials.
Study NCT03564769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AAD SPOTmeⓇ skin cancer screening
Description: All study participants will have participated in the AAD SPOTmeⓇ skin cancer screening program in either 2016 or 2017.
Study NCT00500734 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sample
Description: One time blood draw of 2 teaspoons.
Study NCT01608464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan and docetaxel
Description: combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
Study NCT01608464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, fluorouracil and concurrent radiation therapy
Description: Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
Study NCT02051790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
Study NCT02407873 — intervention group
Intervention type: OTHER
Intervention: Non
Study NCT03844425 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional VFR
Description: Conventional retainers
Study NCT03844425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFR from SLA
Description: SLA has better finishing compared to FDM but it is more expensive.
Study NCT03844425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VFR from FDM
Description: FDM has poorer finishing compared to SLA but it is cheaper.
Study NCT03761485 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Use of Dentifrice Fluoride
Description: Use of few of dentifrice on brushing during a year
Study NCT03761485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Dentifrice Fluoride
Description: Use of few of dentifrice on brushing during a year
Study NCT04658979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary tele-rehabilitation
Description: All the participant will by include in a tele-rehabilitation program who will be based on an 12-week intervention including therapeutic education and self-management sessions and training sessions, delivered through a videoconferencing application. All interventions will be under the supervision of a rehabilitation professional from the Pavillon de prévention des maladies cardiovasculaire (PPMC) and modeled according to the recommendations of the ATS/ERS.
Study NCT02225808 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for anxiety in autism
Study NCT02946892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will be given for 12 weeks and then an exercise test will be performed
Study NCT02946892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given for 12 weeks and then an exercise test will be performed
Study NCT02749162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
Study NCT02749162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol
Study NCT02749162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol
Study NCT02749162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol
Study NCT02749162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: After the block regression, at the first analgetic request the patients received the analgesia protocol
Study NCT02749162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
Study NCT02749162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
Study NCT02749162 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
Study NCT02749162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
Study NCT02781987 — intervention group
Intervention type: OTHER
Intervention: chronic pancreatitis
Description: patients with chronic pancreatitis
Study NCT02085265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
Study NCT02085265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
Study NCT02768402 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Caisson TMVR System
Description: Transcatheter mitral valve replacement is a percutaneous procedure used to treat mitral valve regurgitation with a prosthetic valve implantation.
Study NCT04849117 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound guided Bilateral Transversus Thoracis Muscle Plane block
Description: In the TTMP block group, an ultrasounded guided TTMP block was performed by an anesthesiologist, in ICU, before tracheal tube removal. Between the 4th et 5th rib, on each side, 40 ml of Ropivacaine 2 mg/ml, in association with Clonidine, was injected single-shot in the tranversus thoracis muscle plane. The targets of local anesthetic were the anterior branches of intercostal nerves from T2 to T6. Dexamethasone 8 mg was injected intravenously.
Study NCT01707628 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccination with influenza vaccine
Study NCT02406456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Study NCT01659840 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Red laser
Description: On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
Study NCT01659840 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Infrared laser
Description: On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
Study NCT05510414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological intervention based on psychological capital
Description: Psychological capital would be modified via various training programs in order to manage burnout among nurses. When the four core psychological resources are combined, they may form a higher-order construct that predicts attitudes and performance more strongly than any of the four components by themselves .
Study NCT04240223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilacidin
Description: Brilacidin
Study NCT04240223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04240223 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4Mq 99mTc-DTPA
Description: 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
Study NCT04240223 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 4Mq 99mTc-DTPA
Description: 4Mq technetium-99m (99mTc), complexed with diethylenetriaminepentaacetic acid (DTPA) which prevents absorption of the radioisotope from the gastrointestinal tract
Study NCT02356757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Intervention
Description: The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
Study NCT02356757 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Current Best Practice
Description: CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
Study NCT05423457 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vegan diet
Description: The participants were advised to eat foods in their original type.
Study NCT05423457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegan diet
Description: The participants were advised to eat foods in their original type.
Study NCT01265394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
Study NCT02258217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
Study NCT01853787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Fumarate
Description: Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
Study NCT01853787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
Study NCT03132506 — intervention group
Intervention type: OTHER
Intervention: patient-reported-outcomes
Description: Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
Study NCT01853787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
Study NCT04250116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC monotherapy
Description: Patients enrolled in the NOAC monotherapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 20 mg once daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (15 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
Study NCT04250116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antithrombotic therapy with NOAC and clopidogrel
Description: Patients enrolled in the dual antithrombotic therapy arm would be administered with apixaban 5 mg twice daily or rivaroxaban 15 mg once daily and clopidogrel 75 mg daily for 2 years after randomization. Reduced dose of apixaban (2.5 mg twice daily) or rivaroxaban (10 mg once daily) will be used in patients meeting the pre-defined criteria for dose reduction. Warfarin is allowed to use at the physicians' discretion.
Study NCT04350463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90011
Description: CC-90011
Study NCT01853787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
Study NCT01517633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BirthSign
Description: When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
Study NCT02607501 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implant eCLIPs
Description: Implant eCLIPs at target bifurcation aneurysm
Study NCT03301987 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: 30 minutes per day of therapeutic exercise
Study NCT01351454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACT HEALTHY
Description: ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, \& Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
Study NCT01351454 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nondirective Therapy (NDT)
Description: In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, \& Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
Study NCT00627562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System
Description: Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
Study NCT00669188 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Information absent
Description: Information
Study NCT00669188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Description: Information
Study NCT00225186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visanne (SH T00660AA , BAY86-5258)
Description: Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
Study NCT03624491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal pressure measurement guided ventilation
Description: Use of esophageal pressure measurements to guide mechanical ventilation
Study NCT01885832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous adipose tissue stromal vascular fraction
Study NCT02028507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Study NCT02028507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study NCT02028507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Study NCT02028507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Study NCT04917354 — intervention group
Intervention type: DEVICE
Intervention: Superb-Microvascular imaging
Description: Device: Superb-Microvascular imaging Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
Study NCT04167189 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine gel
Description: Septodont 5% oral lidocaine gel (NDC 0362-0221-10), 75 mg